COALTConnecticut Open Access Land Trust
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Alexion will use its CoALT antibody discovery platform, developed by its wholly owned subsidiary Alexion Antibody Technologies, to validate the targets.
"This drug discovery alliance will provide Alexion with additional validated drug targets, against which Alexion can employ our antibody development technologies, including the CoALT platform," said Dr.
"Alexion's respected CoALT platform will complement CuraGen's functional genomic technologies in the discovery and validation of novel drug targets.